Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gore, S. D.
Right arrow Articles by Herman, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gore, S. D.
Right arrow Articles by Herman, J. G.
[Cancer Research 66, 6361-6369, June 15, 2006]
© 2006 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Combined DNA Methyltransferase and Histone Deacetylase Inhibition in the Treatment of Myeloid Neoplasms

Steven D. Gore1, Stephen Baylin1, Elizabeth Sugar1, Hetty Carraway1, Carole B. Miller1, Michael Carducci1, Michael Grever2, Oliver Galm3, Tianna Dauses1, Judith E. Karp1, Michelle A. Rudek1, Ming Zhao1, B. Douglas Smith1, Jasper Manning1, Anchalee Jiemjit1, George Dover1, Abbie Mays1, James Zwiebel4, Anthony Murgo4, Li-Jun Weng1 and James G. Herman1

1 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland; 2 James Cancer Center of Ohio State University, Columbus, Ohio; 3 Medizinische Klinik IV, Universitaetsklinikum Aachen, Rheinisch-Westfaelische Technische Hochschule Aachen, Aachen, Germany; and 4 Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland

Requests for reprints: Steven D. Gore, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21287. Phone: 410-955-8781; Fax: 410-614-1005; E-mail: gorest{at}jhmi.edu.

Optimal reexpression of most genes silenced through promoter methylation requires the sequential application of DNA methyltransferase inhibitors followed by histone deacetylase inhibitors in tumor cell cultures. Patients with myelodysplastic syndrome or acute myeloid leukemia (AML) were treated with the methyltransferase inhibitor 5-azacitidine (aza-CR) followed by the histone deacetylase inhibitor sodium phenylbutyrate. Major responses associated with cytogenetic complete response developed in patients receiving prolonged dosing schedules of aza-CR. Bisulfite sequencing of the p15 promoter in marrow DNA during the first cycle of treatment showed heterogeneous allelic demethylation in three responding patients, suggesting ongoing demethylation within the tumor clone, but no demethylation in two nonresponders. Six of six responding patients with pretreatment methylation of p15 or CDH-1 promoters reversed methylation during the first cycle of therapy (methylation-specific PCR), whereas none of six nonresponders showed any demethylation. Gene demethylation correlated with the area under the aza-CR plasma concentration-time curve. Administration of both drugs was associated with induction of acetylation of histones H3 and H4. This study provides the first demonstration that molecular mechanisms responsible for responses to DNA methyltransferase/histone deacetylase inhibitor combinations may include reversal of aberrant epigenetic gene silencing. The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials. (Cancer Res 2006; 66(12): 6361-9)




This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
C. Stresemann, I. Bokelmann, U. Mahlknecht, and F. Lyko
Azacytidine causes complex DNA methylation responses in myeloid leukemia
Mol. Cancer Ther., September 1, 2008; 7(9): 2998 - 3005.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. P. Vaughan and J. E. Karp
The Long Road to a Cure for Acute Myelocytic Leukemia: From Intensity to Specificity
J. Clin. Oncol., July 20, 2008; 26(21): 3475 - 3477.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Bonfils, A. Kalita, M. Dubay, L. L. Siu, M. A. Carducci, G. Reid, R. E. Martell, J. M. Besterman, and Z. Li
Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay
Clin. Cancer Res., June 1, 2008; 14(11): 3441 - 3449.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. D. Nimer
Myelodysplastic syndromes
Blood, May 15, 2008; 111(10): 4841 - 4851.
[Abstract] [Full Text] [PDF]


Home page
aacredbookHome page
J.-P. J Issa
DNA Methylation as a Therapeutic Target in Cancer
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 643 - 649.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. M. Klimek, S. Fircanis, P. Maslak, I. Guernah, M. Baum, N. Wu, K. Panageas, J. J. Wright, P. P. Pandolfi, and S. D. Nimer
Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes
Clin. Cancer Res., February 1, 2008; 14(3): 826 - 832.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. S. Palii, B. O. Van Emburgh, U. T. Sankpal, K. D. Brown, and K. D. Robertson
DNA Methylation Inhibitor 5-Aza-2'-Deoxycytidine Induces Reversible Genome-Wide DNA Damage That Is Distinctly Influenced by DNA Methyltransferases 1 and 3B
Mol. Cell. Biol., January 15, 2008; 28(2): 752 - 771.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. R. Fantin and V. M. Richon
Mechanisms of Resistance to Histone Deacetylase Inhibitors and Their Therapeutic Implications
Clin. Cancer Res., December 15, 2007; 13(24): 7237 - 7242.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
A. O. Soriano, H. Yang, S. Faderl, Z. Estrov, F. Giles, F. Ravandi, J. Cortes, W. G. Wierda, S. Ouzounian, A. Quezada, et al.
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome
Blood, October 1, 2007; 110(7): 2302 - 2308.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. Blum, R. B. Klisovic, B. Hackanson, Z. Liu, S. Liu, H. Devine, T. Vukosavljevic, L. Huynh, G. Lozanski, C. Kefauver, et al.
Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia
J. Clin. Oncol., September 1, 2007; 25(25): 3884 - 3891.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Napieralski, K. Ott, M. Kremer, K. Becker, A.-L. Boulesteix, F. Lordick, J. R. Siewert, H. Hofler, and G. Keller
Methylation of Tumor-Related Genes in Neoadjuvant-Treated Gastric Cancer: Relation to Therapy Response and Clinicopathologic and Molecular Features
Clin. Cancer Res., September 1, 2007; 13(17): 5095 - 5102.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Shi, Y. Zhao, T. Ishii, W. Hu, S. Sozer, W. Zhang, E. Bruno, V. Lindgren, M. Xu, and R. Hoffman
Effects of Chromatin-Modifying Agents on CD34+ Cells from Patients with Idiopathic Myelofibrosis
Cancer Res., July 1, 2007; 67(13): 6417 - 6424.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. Merimi, P. Klener, M. Szynal, Y. Cleuter, P. Kerkhofs, A. Burny, P. Martiat, and A. Van den Broeke
Suppression of Viral Gene Expression in Bovine Leukemia Virus-Associated B-Cell Malignancy: Interplay of Epigenetic Modifications Leading to Chromatin with a Repressive Histone Code
J. Virol., June 1, 2007; 81(11): 5929 - 5939.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
H. E. Carraway and S. D. Gore
Addition of Histone Deacetylase Inhibitors in Combination Therapy
J. Clin. Oncol., May 20, 2007; 25(15): 1955 - 1956.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
Y. Huang, E. Greene, T. Murray Stewart, A. C. Goodwin, S. B. Baylin, P. M. Woster, and R. A. Casero Jr
Inhibition of lysine-specific demethylase 1 by polyamine analogues results in reexpression of aberrantly silenced genes
PNAS, May 8, 2007; 104(19): 8023 - 8028.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J.-P. J. Issa
DNA Methylation as a Therapeutic Target in Cancer
Clin. Cancer Res., March 15, 2007; 13(6): 1634 - 1637.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
G. Garcia-Manero
Modifying the Epigenome as a Therapeutic Strategy in Myelodysplasia
Hematology, January 1, 2007; 2007(1): 405 - 411.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
A. H. Ting, K. M. McGarvey, and S. B. Baylin
The cancer epigenome--components and functional correlates
Genes & Dev., December 1, 2006; 20(23): 3215 - 3231.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.